Bruker Corporation: Bruker Expects its FluoroType SARS-CoV-2

Includes robust dual-target SARS-CoV-2 detection and identification of 4 S-gene mutations Reliable detection and even tentative differentiation of Omicron variant expected Validated

Related Keywords

South Africa , United States , Philip Perry , Hain Lifescience Gmb , Bruker Corporation Nasdaq , Business Wire , Molecular Diagnostics , Microbiology Diagnostics Business , Hain Lifescience Gmbh , Bruker Corporation , Bruker Daltonics Microbiology Diagnostics , Bruker , Corporation , Xpects , Luorotype , Cars , Arid , Essay , Reliably , Etect , Tentatively , Differentiate , Micron , Variant ,